Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Dimitris Voliotis, MD
CONTACT
Lead
Radiopharm Theranostics, Ltd
This is a Phase 0/1, First-in-Human (FIH), study to evaluate safety and tolerability of 177Lu-RAD204 in participants with selected solid tumors, and to determine the MTD and/or recommended dose for future exploration. Biodistribution, radiation dosimetry, and preliminary anti-tumor activity of 177Lu-RAD204 will be evaluated. During the Screening Period (up to 4 weeks), participants will receive an imaging dose (low dose of 177Lu-RAD204), to assess dosimetry and to confirm the presence of lesions, prior to enrolling in the Treatment Period. Treatment Period (Phase 1 dose escalation): 177Lu-RAD204 treatment * Participants will receive a treatment dose every 6 weeks (a cycle). * Participants may be treated with multiple cycles, as long as they appear to derive clinical benefit as determined by the Investigator and provided there is adequate clinical safety and organ dosimetry data. * To improve the ratio of tumor to healthy organ distribution of 177Lu-RAD204 an excess of unlabeled RAD204 may be administered.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
